Skip to main content

Chikungunya

5
Pipeline Programs
7
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 7 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Valneva
ValnevaAustria - Vienna
2 programs
1
1
ActivePhase 31 trial
VLA1553Phase 11 trial
Active Trials
NCT03382964Completed120Est. Jul 2019
NCT04650399Completed754Est. Feb 2024
Emergent BioSolutions
1 program
1
ChikungunyaPhase 2
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
ChikungunyaPhase 2
Bharat Biotech
Bharat BiotechIndia - Hyderabad
1 program
1
Inactivated Chikungunya virus vaccine 20 mcgPhase 1Vaccine1 trial
Active Trials
NCT04603131Completed60Est. Jul 2018
Allied Medical
Allied MedicalMO - St. Louis
1 program
Venipuncture for blood drawN/A1 trial
Active Trials
NCT02463968Completed50Est. Jun 2017
Gylden Pharma
Gylden PharmaUK - Abingdon
1 program
PepGNP-ChikVPHASE_11 trial
Active Trials
NCT07394426Not Yet Recruiting40Est. May 2028
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
ChikungunyaPHASE_22 trials
Active Trials
NCT06928753Recruiting1,505Est. Dec 2027
NCT03992872Completed60Est. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Bavarian NordicChikungunya
ValnevaActive
Bavarian NordicChikungunya
Gylden PharmaPepGNP-ChikV
ValnevaVLA1553
Bharat BiotechInactivated Chikungunya virus vaccine 20 mcg
Allied MedicalVenipuncture for blood draw

Clinical Trials (7)

Total enrollment: 2,589 patients across 7 trials

NCT06928753Bavarian NordicChikungunya

Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana

Start: Apr 2025Est. completion: Dec 20271,505 patients
Phase 4Recruiting
NCT04650399ValnevaActive

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

Start: Feb 2022Est. completion: Feb 2024754 patients
Phase 3Completed
NCT03992872Bavarian NordicChikungunya

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

Start: Nov 2019Est. completion: Jan 202160 patients
Phase 2Completed
NCT07394426Gylden PharmaPepGNP-ChikV

A Phase I Study of PepGNP-ChikV in Healthy Volunteers

Start: Aug 2026Est. completion: May 202840 patients
Phase 1Not Yet Recruiting
NCT03382964ValnevaVLA1553

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Start: Mar 2018Est. completion: Jul 2019120 patients
Phase 1Completed
NCT04603131Bharat BiotechInactivated Chikungunya virus vaccine 20 mcg

Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine

Start: Apr 2017Est. completion: Jul 201860 patients
Phase 1Completed
NCT02463968Allied MedicalVenipuncture for blood draw

Chikungunya Arthritis in the Americas

Start: Aug 2016Est. completion: Jun 201750 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 2,589 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.